TD Cowen Raises Danaher (DHR) Price Target to $255

TD Cowen has reiterated its Buy rating on Danaher Corporation with a new price target of $255, a 11.14% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 1:59 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen raised its price target on Danaher Corporation ($DHR) to $255 from $236 on October 13, 2026, and rates the stock "Buy".

Since the rating, $DHR is up 2.8% to date (from the $222.84 close on Oct 13, 2026).

DHR Danaher Corporation

$229.04 +0.00% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, TD Cowen reiterated its Buy rating on Danaher Corporation, setting a price target of $255, up from $236.
TD Cowen's $255 price target implies 11.14% upside from Danaher Corporation's ($DHR) current $229.45 share price.
As of October 16, 2026, Danaher shares were recently trading at $229.45, which is about 10% below the new target.
Danaher has a market cap of about $162.7 billion and a P/E ratio of 41.3, with a next earnings report scheduled for October 21, 2026.

Get $DHR trade alerts by text

We text you when insiders, Congress or big funds trade $DHR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures

TD Cowen has reiterated its Buy rating on Danaher Corporation (NYSE: DHR) on October 13, 2026, and raised its price target to $255 from $236. This change reflects the firm's confidence in Danaher's growth potential, especially in the healthcare sector.

TD Cowen's Call on Danaher

TD Cowen's updated target suggests that Danaher shares are currently undervalued, as they were trading at $229.45 recently. This new target is about 10% above the recent trading price. The firm maintains a positive outlook on Danaher's business drivers, which include its strong performance in diagnostics and life sciences.

Other Institutional Activity in Danaher

Several other institutional investors have also shown interest in Danaher. Blackrock Inc. holds about 55,084,630 shares worth approximately $12.6 billion after increasing its stake by 3,444,403 shares, a 6.7% rise. Vanguard Capital Management LLC has 41,377,076 shares valued at about $9.5 billion, with a slight increase of 250,870 shares, or 0.6%. FMR, LLC also added significantly, with a 31.1% increase, bringing its total to around 29,540,895 shares worth about $6.8 billion.

Danaher Corporation Stock Up 2.1%

As of October 16, 2026, Danaher shares are trading at $229.45, which is above their 50-day moving average by about 7.6% and above the 200-day moving average by about 14.0%. However, the stock is about 5.5% below its 52-week high of $242.8. With a market cap of approximately $162.7 billion and a P/E ratio of 41.3, Danaher remains a significant player in the healthcare sector.

12-month forecast

$DHR price target

Danaher Corporation daily closes and this analyst's $255 target. Not advice.

Recent Earnings

Danaher reported trailing twelve-month revenue of approximately $25.1 billion, with a net margin of 15.9% and an ROE of 7.6%. The company's revenue growth year-over-year stands at 5.5%. The next earnings report is scheduled for October 21, 2026, which will provide further insights into its financial performance.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

F 30/100

Reported Apr 21, 2026

Forward outlook
5 target cuts vs 1 raises.
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
1 target raise, 5 target cuts.
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.

Earnings Call Summary

Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.

Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.

Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.

Insider Buying and Selling at Danaher Corporation

Recent insider activity includes Rainer M. Blair, the CEO, who sold 58,255 shares valued at about $12.7 million on August 21, 2026. Additionally, Director Alan G. Spoon sold 1,358 shares for roughly $237,207 on May 1, 2026. This activity occurred before the recent analyst updates.

Analysts Set New Price Targets

On October 1, 2026, Guggenheim maintained a Buy rating with a target of $250. RBC Capital also kept its Outperform rating on October 5, with a target of $250. Barclays maintained an Overweight rating on October 7 and raised its target to $255. On the same day as TD Cowen's update, Morgan Stanley maintained its Overweight rating with a target of $240.

About Danaher Corporation

Danaher Corporation designs and manufactures a wide range of professional, medical, research, and industrial products and services. The company operates through its Biotechnology, Life Sciences, and Diagnostics segments, serving customers in the U.S., China, and globally. Danaher's strong market position and ongoing innovations are key drivers for its performance.

Bottom Line

Investors should keep an eye on Danaher's upcoming earnings report on October 21, 2026, which will provide further insights into its financial performance. With several analysts supporting a Buy rating, Danaher appears well-positioned for continued growth.